RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer
SEOUL, South Korea — The combination of avutometinib and defactinib achieved “exceptionally” high response rates in heavily pretreated patients with recurrent low-grade serous ovarian cancer (LGSOC), according to the ENGOT-ov60/GOG-3052/RAMP 201 trial. Moreover, responses were consistently high no matter how many previous lines of therapy patients received prior to study entry, reported Rachel N. Grisham […]
Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer
SEOUL, South Korea — Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to data from the SIENDO trial. The updated, long-term data from the phase III study showed that, at a median follow-up of 25.3 months, median PFS was 27.4 […]